Assessing trends in breast cancer survival among young women who are largely unaffected by breast cancer screening will provide important information regarding improvements in the effectiveness of cancer care for breast cancer in the last few decades. METHODS: The cohort for this study consisted of women who were diagnosed with breast cancer between ages 20 and 39 years from the Surveillance, Epidemiology, and End Results program's 9-registry areas from 1975 to 2015. Trends in the breast cancer incidence rate and survival were assessed among young women. RESULTS: Among women aged 20 to 39 years, breast cancer incidence increased from 24.6 per 100,000 in 1975 to 31.7 per 100,000 in 2015 (annual percent change, 0.5; 95% confidence in- 
INTRODUCTION
Breast cancer is the most frequently diagnosed cancer excluding skin cancers and the second leading cause of cancer death after lung cancer among women in the United States.
1,2 Advances in systemic therapy for breast cancer have greatly improved patient survival rates. 3 However, quantifying the effectiveness of these advances on cancer survival rates at the population level is challenging, because mammography screening also contributes to survival improvement. 4, 5 Collaborative model studies of breast cancer screening strategies suggest that, compared with no screening, annual screening in women aged 50 to 74 years can reduce one-third of breast cancer mortality and equals approximately 100 quality-adjusted life years gained per 1000 women screened. [6] [7] [8] Biennial screening results in less benefit in terms of mortality reduction but also produces fewer false-positive results compared with annual mammography among women aged 50 to 74 years. Both screened and unscreened women experience reductions in breast cancer mortality, [9] [10] [11] suggesting that other factors (eg, cancer treatment) also are responsible for the reduced mortality. Welch et al evaluated the relative contributions of breast cancer screening and improved cancer therapy to the reduction in breast cancer mortality among women aged 40 years and older. Those investigators concluded that more screening tends to overdiagnose breast tumors instead of providing early detection and that most of the mortality reduction can be ascribed to improved cancer therapy.
Cancer September 1, 2018 National guidelines for breast cancer screening with mammography usually recommend starting no earlier than age 40 years for women who have an average risk of developing breast cancer, [12] [13] [14] [15] [16] whereas women at high risk may start mammography screening at age 30 years or magnetic resonance imaging screening at age 25 years. 17, 18 Because breast cancer screening is sparse among young women aged <40 years, improvements in breast cancer survival for this population are mostly attributable to advances in breast cancer treatment. In the current study, we used data from the Surveillance, Epidemiology, and End Results (SEER) program's 9-registry areas from 1975 through 2015 to assess the trends in breast cancer incidence rates among young women diagnosed at ages 20 to 39 years and to evaluate their improvements in breast cancer survival.
MATERIALS AND METHODS
The study cohort consisted of young women who had cancer diagnosed between ages 20 and 39 years from the SEER 9-registry areas-including California (San Francisco and Oakland), Connecticut, Georgia (Atlanta only), Hawaii, Iowa, Michigan (Detroit only), New Mexico, Utah, and Washington (Seattle and Puget Sound region)-which cover approximately 10% of the US population. 19 Details of the SEER program have been published elsewhere. 20, 21 We excluded data from the first 2 years (SEER 1973 (SEER -1974 , which are generally not considered reliable, and used the most recent SEER data for our analyses. This study was not considered human subjects research by the Institutional Review Board at The University of Texas Medical Branch (Galveston, TX).
The SEER registry collects demographic and cancer diagnosis information. Data about breast cancer deaths are derived from information recorded on death certificates and ascertained from the US Centers for Disease Control and Prevention (CDC) National Center for Health Statistics (NCHS). Follow-up was through December 2015. Demographic characteristics of patients with cancer originally were extracted from medical records and submitted to cancer registries. The demographic characteristics used for this analysis included sex, race/ethnicity, and age at diagnosis. Age at death was obtained from death certificates. Race was categorized as white, black, Asian/Pacific Islander, and other; and ethnicity was classified as Hispanic or non-Hispanic. Hispanic ethnicity for all patients with cancer was identified by using the North American Association of Central Cancer Registries' Hispanic/Latino identification algorithm. 22 SEER historic stage A was used to classify invasive breast cancers according to stage at diagnosis as localized (confined to breast tissue and fat, including nipple and/or areola), regional (direct extension or ipsilateral regional lymph nodes involved), metastatic (distant lymph nodes involved, further contiguous extension, or metastasis), and unknown stage. 23 Ductal carcinoma in situ (DCIS) was identified using International Classification of Diseases for Oncology (3rd edition) codes (8201/2, 8230/2, 8401/2, 8500/2, 8501/2, 8503/2, 8504/2, 8507/2, 8521/2, 8522/2, and 8523/2).
Statistical Analysis
Breast cancer incidence rates were calculated as cases per 100,000 persons and age-adjusted to the 2000 US standard population using the SEER*Stat statistical software package (version 8.3.5). 19 Confidence intervals (CIs) were calculated using the Tiwari method. 24 Joinpoint regression models 25 were fitted based on annual incidence data using the National Cancer Institute's Joinpoint Regression Analysis program, version 4.6.0. This analysis program selected the best-fitting log-linear regression model to identify the conjunctures (calendar years) when the annual percent change (APC) changed significantly, allowing for the minimum number of joinpoints necessary to fit the data. The APC was calculated as (exp[β] − 1) * 100, where the regression coefficient (β) was estimated by fitting a least-squares regression line to the natural logarithm of the rates using the calendar year as a regressor variable. Tests of the statistical significance of APC and differences between APCs for 2 time periods were based on methods proposed by Kleinbaum and colleagues and were performed using the SEER*Stat software program. 26 We excluded cases identified only from autopsy records or death certificates for the assessment of breast cancer survival. Only patients who had microscopically confirmed, primary breast cancer were selected. The 5-year survival probability (overall or cause-specific) was calculated using 60 monthly intervals in SEER*Stat. The relative survival of women with breast cancer in the absence of other causes of death was calculated using survival life tables as the ratio of the proportion of observed survivors (all causes of death) in a cohort of patients with cancer to the proportion of expected survivors in a comparable cohort of cancer-free individuals. SEER*Stat software used expected life tables instead of a cohort of cancer-free individuals, assuming that the
cancer deaths were a negligible proportion of all deaths. Individuals who died from causes other than breast cancer were considered to be censored when we estimated breast cancer-specific survival. Cox proportional hazard models were fitted to compare differences in 5-year survival probability across time by stage at diagnosis, controlling for age at diagnosis and race/ethnicity. Hazard ratios (HRs) and 95% CIs were estimated from the Cox model. Kaplan-Meier curves were plotted to illustrate differences in the cumulative probability of death across time. Because high-risk women 17, 18 may start breast cancer screening with mammograms at age 30 years or with magnetic resonance imaging at age 25 years, 18 we performed sensitivity analyses in the groups aged 20 to 29 years and 30 to 39 years. Statistical significances were determined as 2-sided P values < .05.
RESULTS
The age-adjusted incidence of breast cancer increased from 24. Table 1 ).
Sensitivity Analyses
Sensitivity analyses in the groups aged 20 to 29 years and 30 to 39 years yielded similar results (Supporting Tables 1-4) . Among women aged 20 to 29 years, the ageadjusted incidence of metastatic breast cancer was low, but it increased significantly from 1975 to 2015 (APC, 3.8; 95% CI, 2.7-4.9). No significant changes in the trends in incidence for either DCIS or metastatic cancer were observed during this period (Fig. 3A) . Among women aged 30 to 39 years, the increasing trend for adjusted incidence of DCIS changed significantly in 1989 and 2005, and the APCs for age-adjusted incidence of metastatic breast cancer increased significantly in 2005 (Fig. 3B) .
DISCUSSION
By using data from SEER, we systematically compared trends in breast cancer mortality by tumor characteristics at diagnosis among young women between ages 20 and 39 years. The main findings were the significant increase in breast cancer incidence and improved survival for patients with breast cancer in the last 4 decades. The improvement in survival reached a plateau most recently; however, but among young women with metastatic cancer, survival continued to improve throughout the period from 1975 to 2015. The significant reduction in the probability of dying from breast cancer among young women most likely can be attributed to advances in breast cancer therapy, because these populations typically were not screened. 3, 27 Cancer September 1, 2018
In the past few decades, treatment for patients with breast cancer has undergone substantial improvement. Better tolerated therapies have been replacing ablative surgery and aggressive chemotherapy. 28 Tamoxifen and other hormone therapies, cytotoxic therapies, 29 and targeted therapies 28 have significantly reduced breast cancer recurrence and mortality and improved the quality of life for patients with breast cancer. The introduction of taxanes in the mid-1990s greatly improved survival for patients with both early and advanced tumors. 30, 31 Human epithelial growth factor receptor 2 (HER2)-directed therapies, such as the classic anti-HER2 antibody trastuzumab, have become available since late 1990s for the treatment of HER-2-positive, advanced breast cancer and have significantly reduced cancer deaths in these patients. 32, 33 Improved breast cancer care Cancer September 1, 2018 using a multidisciplinary medical approach also has contributed significantly to these improvements. 34 In the current study, we observed that, among young women with breast cancer mortality, has decreased by 60% to 70% in the last 4 decades for each stage of breast cancer. Although our study revealed improvements in cancer survival among women who had breast cancer diagnosed at an age range that, according to most guidelines, was younger than the recommended screening-initiation age (especially those diagnosed at ages 20-29 years), we cannot definitively conclude that all of these improvements are attributable to improved cancer treatments. Advances in breast cancer treatments and cancer care are likely to be the major contributors. Other factors, such as dynamic changes in breast cancer risk factors (eg, breastfeeding, age at menarche, parity, and oral contraceptive use), lifestyle modifications (diet, alcohol consummation, smoking, exercise, etc), and biologic characteristics of the cancers, also may contribute to the improvements in breast cancer survival. [35] [36] [37] [38] [39] In general, our findings demonstrate a degree of survival improvement in women aged <40 years with invasive breast cancer similar to that observed in older women. In the screened population (women aged ≥40 years), nearly all of the mortality Abbreviation: CI, confidence interval. a Overall survival was defined as the probability of surviving all causes of death. b Cancer-specific survival was defined as surviving breast cancer in the absence of other causes of death and was calculated by specifying death caused by breast cancer; individuals who died of causes other than breast cancer were considered to be censored. c Relative survival of women with breast cancer in the absence of other causes of death was calculated using survival life tables as the ratio of the proportion of observed survivors (all causes of death) in a cohort of patients with cancer to the proportion of expected survivors in a comparable cohort of cancer-free individuals.
Cancer September 1, 2018 reduction also was caused by treatment advances and not screening. 3 Thus, these observations may have direct implications for breast cancer mammography screening.
One interesting finding of this study is that cancer survival improvements reached a plateau but continued to increase among women with metastatic breast cancer in recent years. These trends may reflect no major changes in the adjuvant standard of care (for adjuvant chemotherapy or hormone therapy) in the years from 2010 to 2015s. 40 In contrast, there have been continued advances in the treatment of metastatic breast cancer (pertuzumab, 41 everolimus, 42, 43 and ado-trastuzumab emtansine 44 in recent years), which is why we observed greater changes in patients who had metastatic disease, then fewer changes in those who had regional disease, and even fewer changes in those who had localized Cancer September 1, 2018 disease. Stage migration also may contribute to the improved survival observed in patients with metastatic cancer. Because patients who have lower stage disease usually have better survival, survival will be artificially elevated in the category of metastatic tumor when stage migration occurs. Patients with lower stage (eg, regional) disease may be upstaged to metastatic tumor status because of improved diagnostic imaging, increasing use of imaging studies for staging, and changes in staging classification. Routine use of sentinel lymph node biopsy, however, may lower the stage classification compared with radical lymph node dissection. Johnson et al assessed the incidence of metastatic breast cancer among young women in the United States and concluded that the increasing trend in cancer incidence is unlikely because of stage migration, although stage migration may have made some small contribution to the increasing trend after 1995. 45 Therefore, the contribution of stage migration to improved survival in patients with metastatic cancer may be minimal.
Early detection followed by timely treatment can effectively improve survival for women with breast cancer. Among young women aged 20 to 39 years, breast cancer screening with mammography is not recommended for average-risk women, and only women at high risk for developing breast cancer may start mammogram screening at an early age. 17, 18 These high-risk women include those with a history of chest irradiation between ages and 10 and 30 years, a known genetic predisposition for breast cancer, or a strong family history of the disease. Young patients with breast cancer are more likely to carry harmful mutations of BRCA1, BRCA2, or other cancer-related genes. 46 However, those mutations may not negatively affect their survival. 47, 48 Identifying mutation carriers before they develop breast cancer offers an opportunity to start screening early or receive prophylactic treatments to prevent breast cancer. Genetic testing in young patients with cancer also enables them to receive tailored treatments based on their tumor type and the molecular characteristics. 49 Both the Precision Medicine Initiative and the Cancer Moonshot place strong emphasis on genetic risks for aggressive breast cancer, cancer prevention, early detection, tailored interventions, and individualized cancer care with the ultimate goals of reducing cancer incidence and improving survival. 50, 51 The strength of the current study is that we used data from a large cohort of young women with breast cancer. Data on cancer diagnosis date, stage, and patient sociodemographic characteristics enabled us to examine changes in breast cancer incidence rates and survival across subpopulations and over time. Assessing trends in breast cancer survival among young women allowed us to focus on a population largely unaffected by screening; thus, estimates from our study will provide important information regarding improvements in the effectiveness of medical care for breast cancer in the last few decades.
This study also had several limitations. We used data from young women in the SEER 9-registry areas, so that our findings may not be applicable to other areas in the United States and women in other age groups. In addition, information on mammogram screening was not available in SEER; however, only women at high risk for developing breast cancer were recommended to receive mammography screening in their 30s. We also performed sensitivity analyses in younger patients diagnosed before age 30 years and observed similar improvements in survival. Cancer September 1, 2018 In summary, the current study reveals that there were significant improvements in survival between 1975 and 2015 among young women with breast cancer. The survival improvement observed in these populations is likely driven by advances in breast cancer treatments rather than screening. We also observed that, with the exception of metastatic breast cancer, the improvements in survival reached a plateau between 2005 and 2009. 
